Targeting tumor angiogenesis with histone deacetylase inhibitors
- 1 August 2009
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 280 (2) , 145-153
- https://doi.org/10.1016/j.canlet.2008.11.012
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Integrins in angiogenesis and lymphangiogenesisNature Reviews Cancer, 2008
- Sirtuins: critical regulators at the crossroads between cancer and agingOncogene, 2007
- Sirtuins in mammals: insights into their biological functionBiochemical Journal, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Angiogenesis in life, disease and medicineNature, 2005
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971